Evidence map›Paper›PMID 38521934›Full record

ArticleBMC complementary medicine and therapies2024

Efficacy and mechanisms of cannabis oil for alleviating side effects of breast cancer chemotherapy (CBC2): protocol for randomized controlled trial.

May Soe Thu, Krit Pongpirul, Mawin Vongsaisuwon, Chanida Vinayanuwattikun, Kamonwan Banchuen, Thunnicha Ondee, Sunchai Payungporn, Phanupong Phutrakool, Preecha Nootim, Pajaree Chariyavilaskul and 3 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

May Soe ThuJoint Chulalongkorn University-University of Liverpool PhD Programme in Biomedical Sciences and Biotechnology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Krit PongpirulDepartment of Infection Biology & Microbiomes, University of Liverpool, Liverpool, UK. doctorkrit@gmail.com.
Mawin VongsaisuwonDepartment of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Chanida VinayanuwattikunKing Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Kamonwan BanchuenCenter of Excellence in Preventive and Integrative Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Thunnicha OndeeDepartment of Infection Biology & Microbiomes, University of Liverpool, Liverpool, UK.
Sunchai PayungpornDepartment of Biochemistry, Faculty of Medicine, Center of Excellence in Systems Microbiology,, Chulalongkorn University, Bangkok, 10330, Thailand.
Phanupong PhutrakoolCenter of Excellence in Preventive and Integrative Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Preecha NootimDepartment of Thai Traditional and Alternative Medicine, Ministry of Public Health, Nonthaburi, Thailand.
Pajaree ChariyavilaskulDepartment of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Sarocha CherdchomCenter of Excellence in Preventive and Integrative Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Kulthanit WanaratnaDepartment of Thai Traditional and Alternative Medicine, Ministry of Public Health, Nonthaburi, Thailand.
Nattiya HirankarnDepartment of Microbiology, Faculty of Medicine, Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University, Bangkok, Thailand.
Chulalongkorn University · THMinistry of Public Health · THUniversity of Liverpool · GB

Funding

Ministry of Public Health KPT.14/2566
6 · The paper itself

Abstract

backgroundIn a pilot study using both cannabidiol (CBD) and tetrahydrocannabinol (THC) as single agents in advanced cancer patients undergoing palliative care in Thailand, the doses were generally well tolerated, and the outcome measure of total symptom distress scores showed overall symptom benefit. The current study aims to determine the intensity of the symptoms experienced by breast cancer patients, to explore the microbiome profile, cytokines, and bacterial metabolites before and after the treatment with cannabis oil or no cannabis oil, and to study the pharmacokinetics parameters and pharmacogenetics profile of the doses.

methodsA randomized, double-blinded, placebo-controlled trial will be conducted on the breast cancer cases who were diagnosed with breast cancer and currently receiving chemotherapy at King Chulalongkorn Memorial Hospital (KCMH), Bangkok, Thailand. Block randomization will be used to allocate the patients into three groups: Ganja Oil (THC 2 mg/ml; THC 0.08 mg/drop, and CBD 0.02 mg/drop), Metta Osot (THC 81 mg/ml; THC 3 mg/drop), and placebo oil. The Edmonton Symptom Assessment System (ESAS), Food Frequency Questionnaires (FFQ), microbiome profile, cytokines, and bacterial metabolites will be assessed before and after the interventions, along with pharmacokinetic and pharmacogenetic profile of the treatment during the intervention.

trial registrationTCTR20220809001.

Indexed as

Breast NeoplasmsCannabidiolCannabisCytokinesFemaleHumansPilot ProjectsRandomized Controlled Trials as TopicThailandCannabidiolCytokinesBreast CancerCannabisMicrobiotaQuality of Life

Identifiers

PMID38521934
PMCPMC10960413
OpenAlexW4393115291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.